Pharmacological agonists targeting this family of receptors, particularly GLP-1R, have revolutionized type 2 diabetes (T2D) and obesity treatment, and further roles are emerging in the treatment of other related disorders such as metabolic dysfunction–associated steatotic liver disease (MASLD) (3). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.